Venclexta (venetoclax) — Highmark
Small Lymphocytic Lymphoma (SLL)
Initial criteria
- age ≥ 18 years
- diagnosis of CLL (ICD-10 C91.1) OR SLL (ICD-10 C83.0)
Reauthorization criteria
- prescriber attests that the member is tolerating therapy AND has experienced a therapeutic response defined as either disease improvement OR delayed disease progression
Approval duration
12 months